222 related articles for article (PubMed ID: 25271001)
1. Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma.
Li L; Liu Y; Guo Y; Liu B; Zhao Y; Li P; Song F; Zheng H; Yu J; Song T; Niu R; Li Q; Wang XW; Zhang W; Chen K
Hepatology; 2015 Feb; 61(2):574-84. PubMed ID: 25271001
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-148a-3p inhibits progression of hepatocelluar carcimoma by repressing SMAD2 expression in an Ago2 dependent manner.
Huang Z; Wen J; Yu J; Liao J; Liu S; Cai N; Liang H; Chen X; Ding Z; Zhang B
J Exp Clin Cancer Res; 2020 Aug; 39(1):150. PubMed ID: 32746934
[TBL] [Abstract][Full Text] [Related]
3. microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression.
Heo MJ; Kim YM; Koo JH; Yang YM; An J; Lee SK; Lee SJ; Kim KM; Park JW; Kim SG
Oncotarget; 2014 May; 5(9):2792-806. PubMed ID: 24798342
[TBL] [Abstract][Full Text] [Related]
4. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
Xia H; Ooi LL; Hui KM
PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
[TBL] [Abstract][Full Text] [Related]
5. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma.
Yan H; Dong X; Zhong X; Ye J; Zhou Y; Yang X; Shen J; Zhang J
Mol Carcinog; 2014 Dec; 53(12):960-9. PubMed ID: 23861222
[TBL] [Abstract][Full Text] [Related]
6. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling.
Zhang JP; Zeng C; Xu L; Gong J; Fang JH; Zhuang SM
Oncogene; 2014 Jul; 33(31):4069-76. PubMed ID: 24013226
[TBL] [Abstract][Full Text] [Related]
8. Decrease expression and clinicopathological significance of miR-148a with poor survival in hepatocellular carcinoma tissues.
Ajdarkosh H; Dadpay M; Yahaghi E; Pirzaman ER; Fayyaz AF; Darian EK; Mokarizadeh A
Diagn Pathol; 2015 Aug; 10():135. PubMed ID: 26248880
[TBL] [Abstract][Full Text] [Related]
9. HBX-induced miR-5188 impairs FOXO1 to stimulate β-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma.
Lin X; Zuo S; Luo R; Li Y; Yu G; Zou Y; Zhou Y; Liu Z; Liu Y; Hu Y; Xie Y; Fang W; Liu Z
Theranostics; 2019; 9(25):7583-7598. PubMed ID: 31695788
[TBL] [Abstract][Full Text] [Related]
10. miR-192-5p Silencing by Genetic Aberrations Is a Key Event in Hepatocellular Carcinomas with Cancer Stem Cell Features.
Gu Y; Wei X; Sun Y; Gao H; Zheng X; Wong LL; Jin L; Liu N; Hernandez B; Peplowska K; Zhao X; Zhan QM; Feng XH; Tang ZY; Ji J
Cancer Res; 2019 Mar; 79(5):941-953. PubMed ID: 30530815
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between liver-related microRNAs and Wnt/β-catenin pathway in hepatocellular carcinoma patients.
Ashmawy AM; Elgeshy KM; Abdel Salam ET; Ghareeb M; Kobaisi MH; Amin HAA; Sharawy SK; Abdel Wahab AHA
Arab J Gastroenterol; 2017 Sep; 18(3):144-150. PubMed ID: 28958640
[TBL] [Abstract][Full Text] [Related]
12. microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit.
Shi X; Liu TT; Yu XN; Balakrishnan A; Zhu HR; Guo HY; Zhang GC; Bilegsaikhan E; Sun JL; Song GQ; Weng SQ; Dong L; Ott M; Zhu JM; Shen XZ
Oncogene; 2020 Aug; 39(35):5768-5781. PubMed ID: 32719439
[TBL] [Abstract][Full Text] [Related]
13. Novel role of LINC01013/miR-6795-5p/FMNL3 axis in the regulation of hepatocellular carcinoma stem cell features.
Wang W; Xu S; Di Y; Zhang Z; Li Q; Guo K; Lv Y; Wang B
Acta Biochim Biophys Sin (Shanghai); 2021 May; 53(6):652-662. PubMed ID: 33847733
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis.
Xu X; Fan Z; Kang L; Han J; Jiang C; Zheng X; Zhu Z; Jiao H; Lin J; Jiang K; Ding L; Zhang H; Cheng L; Fu H; Song Y; Jiang Y; Liu J; Wang R; Du N; Ye Q
J Clin Invest; 2013 Feb; 123(2):630-45. PubMed ID: 23321675
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
[TBL] [Abstract][Full Text] [Related]
16. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells.
Ji J; Yamashita T; Budhu A; Forgues M; Jia HL; Li C; Deng C; Wauthier E; Reid LM; Ye QH; Qin LX; Yang W; Wang HY; Tang ZY; Croce CM; Wang XW
Hepatology; 2009 Aug; 50(2):472-80. PubMed ID: 19585654
[TBL] [Abstract][Full Text] [Related]
17. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
Zheng F; Liao YJ; Cai MY; Liu YH; Liu TH; Chen SP; Bian XW; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2012 Feb; 61(2):278-89. PubMed ID: 21672940
[TBL] [Abstract][Full Text] [Related]
18. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival.
Luk JM; Burchard J; Zhang C; Liu AM; Wong KF; Shek FH; Lee NP; Fan ST; Poon RT; Ivanovska I; Philippar U; Cleary MA; Buser CA; Shaw PM; Lee CN; Tenen DG; Dai H; Mao M
J Biol Chem; 2011 Sep; 286(35):30706-30713. PubMed ID: 21737452
[TBL] [Abstract][Full Text] [Related]
19. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ
World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561
[TBL] [Abstract][Full Text] [Related]
20. The repressive effect of miR-148a on TGF beta-SMADs signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells.
Jiang F; Mu J; Wang X; Ye X; Si L; Ning S; Li Z; Li Y
PLoS One; 2014; 9(5):e96698. PubMed ID: 24806207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
